Statement on lanreotide in the U.S.

PARIS, FRANCE, 20 December 2021 – 6:00 PM CET – Ipsen has learned that Cipla Limited and its subsidiary Cipla USA, Inc. has received final approval of a lanreotide product from the U.S. Food and Drug Administration; the FDA approval was based on a New Drug Application (NDA) submitted under the 505(b)(2) filing pathway. There is no change to Ipsen’s mid-term financial outlook to 2024

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022